Minoryx (Private) developing a best-in-class PPARg agonist, leriglitazone (MIN-102), for the treatment of rare CNS diseases. MIN-102 is currently in a pivotal Phase 2/3 study for life threatening, orphan chronic subtype adrenomyeloneuropathy (AMN, adult form of X-ALD) and in a Phase 2 study for Friedrich’s Ataxia (FRDA); top line data for both expected by end of 2020 and marketing authorization filing anticipated in US/EU by 2021. Leriglitazone has Orphan Drug Status in EU and US for X-ALD.
Phase III, Phase l or ll
Av. Ernest Lluch 32, TCM3
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Summer 2020 NYC Private Company Showcase
New York, NY,
August 10, 2020